Preclinical models confirmed strong pharmacodynamic responses and anti-tumor activity of SGR-3515 as a monotherapy and as part of combination therapy with other agents. SGR-3515 is a Wee1/Myt1 dual inhibitor with a differentiated biochemical, biophysical and functional profile, with sustained ...
and we believe the future of our therapeutics portfolio is very promising.” SGR-3515 Data at ENA 2024 The presentation (Abstract # 147), “Discovery of SGR-3515, a first-in-class Wee1/Myt1 inhibitor with differentiated